Celularity Receives Nasdaq Notice Regarding Form 10-Q
The Notice received from Nasdaq has no immediate effect on the listing or trading of the Company's shares. Nasdaq has provided the Company 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, then Nasdaq may grant the Company an exception until November 17, 2025, to regain compliance with the Nasdaq Listing Rules.
The Company continues to work diligently to complete its Form 10-Q for the period ended March 31, 2025, after which the Company anticipates maintaining compliance with its SEC reporting obligations.
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta's unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information, visit www.celularity.com.
Forward-Looking Statements
This press release includes 'forward-looking statements' (as defined under Federal securities laws). These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as 'anticipate,' 'believe,' 'can,' 'could,' 'continue,' 'expect,' 'improving,' 'may,' 'observed,' 'potential,' 'promise,' 'should,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks,' and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption 'Risk Factors' in Celularity's annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity's current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity's views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Carlos RamirezSenior Vice President, Celularity Inc.Carlos.ramirez@celularity.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
20 minutes ago
- Business Insider
Banzai announces one-for-ten reverse stock split
Banzai (BNZI) announced that effective at market open on July 8, the company will effect a one-for-ten reverse stock split of its outstanding Class A Common Stock and Class B Common Stock. The reverse stock split is primarily intended to increase the per share price of Banzai's Class A Common Stock and maintain compliance with the Nasdaq minimum bid price requirement. The company's Class A common stock will continue to trade. Upon the effectiveness of the reverse stock split, every ten shares of issued and outstanding common stock before the open of business on July 8, will be combined into one issued and outstanding share of common stock, with no change in par value per share. The company's Class A common stock will open for trading on Nasdaq on July 8 on a post-split basis but will trade under a new CUSIP Number. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week.
Business Wire
28 minutes ago
- Business Wire
Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ('ISS') has joined Glass, Lewis & Co. ('Glass Lewis') in recommending that SINOVAC shareholders vote to KEEP the current SINOVAC Board in place by voting the WHITE proxy card 'AGAINST' the election of the Reconstituted Imposter Former Board Slate at the upcoming Special Meeting of Shareholders (the 'Special Meeting'). The SINOVAC Board issued the following statement in response to ISS' recommendation: 'We are thrilled that independent proxy advisors ISS and Glass Lewis recommended shareholders vote to KEEP SINOVAC's current Board in place and OPPOSE the Reconstituted Imposter Former Board Slate. In making their recommendations, ISS and Glass Lewis both recognized the swift actions the current SINOVAC Board has taken to restore fairness and deliver value to SINOVAC's rightful shareholders, and they have criticized the Imposter Former Board's abject governance failures that robbed value from SINOVAC shareholders during its seven-year 'de facto' tenure. 'The facts speak for themselves: over the past four months, the current SINOVAC Board has demonstrated its commitment to righting the wrongs of the Imposter Former Board. The current Board has declared a US$55.00 per common share special cash dividend and has continued to lay the groundwork for additional distributions, is working with NASDAQ to resume trading, and is launching a formal exploration of a future listing on the Stock Exchange of Hong Kong to promote liquidity and support shareholder value creation. 'In contrast, the Imposter Former Board, in close coordination with SAIF, Advantech/Prime Success ('Advantech/Prime') and Vivo Capital (together, 'the Dissenting Investor Group'), continue to attempt to derail our progress through misleading rhetoric, baseless claims and frivolous legal actions. Their self-serving objective is clear: regain control of SINOVAC and deprive common shareholders of their rightful dividend payments. 'We urge shareholders to follow the recommendations of both leading independent proxy advisory firms by voting AGAINST the election of the Reconstituted Imposter Former Board on the WHITE proxy card.' Highlights from the ISS Report include 1 (emphasis added): SUPERIORITY OF THE CURRENT BOARD '[T]he [current] board appears to be working to pay SVA shareholders their fair share of dividends, and to resume trading of the company's shares, which are the two most pressing issues currently facing SVA shareholders.' DIVIDEND PAYMENTS 'In engagement with ISS, when [the dissident's] nominees who were former board members were asked why they did not pay dividends to SVA shareholders when they were board members, they gave several answers. […] However, neither reason is reflected in the company's statements in its annual report for 2023, in which it states that the company 'has no intention to distribute dividends in the near future.' When the available facts outlined in the sections above are taken into account, it is difficult to rationalize the conduct of the former board with regard to dividend distributions to SVA shareholders. ' 'The former board […] presided over transactions that enabled the payment of billions of dollars in dividends to minority shareholders of SLS, all while it told SVA shareholders that it had no plans to pay dividends to them.' POISON PILL AND NASDAQ TRADING HALT 'It appears that the former board used the poison pill as an entrenchment mechanism. The former board declared that it had been triggered over one year prior, and acted to issue shares accordingly. In doing so, it appears that the former board was using it against shareholders who had cast more votes for their candidates at the 2018 AGM than had been cast for management nominees. In that sense, it appears that the former board was using the pill to overturn the will of a majority of shareholders. ' 'During this contest, the dissident has not provided a convincing explanation for why the former board could not remove the trading halt.' '[…] the more than decade-long record of former board members on the dissident slate paints a picture of a board that adopted and triggered a poison pill to disenfranchise shareholders, which led to the trading halt of the company's shares.' IMPOSTER FORMER BOARD'S SELF-DEALING 'Shareholders can reasonably question whether the former SVA board acted appropriately in its appointment of SLS board members, who presumably approved the sale of nearly 41 percent of the entity at a time when SLS was generating healthy profits.' At the Special Meeting, shareholders will have the chance to send a clear message to the Dissenting Investor Group: SINOVAC will no longer be held captive to their self-dealing. SINOVAC's Board urges shareholders to protect their investment and the future of their Company by voting the WHITE proxy card today 'AGAINST' Proposals 1 and 2 at the Special Meeting. For more details on the misdeeds and shareholder harm caused by the Imposter Former Board and Dissenting Investor Group, visit our website 1 Permission to use quotations was neither sought nor obtained. Expand Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! The Special Meeting of Shareholders will be held on Wednesday, July 9, 2025, at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025, at 8:00 p.m. Atlantic Standard Time). Valid shareholders of record as of the close of business on May 19, 2025, are entitled to vote at the meeting. If you have any questions about locating your control number or voting your shares, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Business Insider
34 minutes ago
- Business Insider
Ree Automotive receives noncompliance letter from Nasdaq
Ree Automotive (REE) reported that the company received a letter from the Nasdaq Stock Market indicating that the company is currently not in compliance with Nasdaq Rule 5450. In particular, the letter stated that the company's closing bid price for its Class A ordinary shares has been below $1.00 per share for the last 30 consecutive business days beginning on May 15 through June 27. Nasdaq provides REE with a period of 180 calendar days to regain compliance. According to the letter, the company has until December 29 to regain compliance with the minimum bid price requirement. The company will regain compliance, if at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum period of ten consecutive business days, in which case the company will be provided with a written confirmation of compliance from Nasdaq and this matter will be closed. If the company does not demonstrate compliance prior to the end of the 180-day period ending December 29, Nasdaq's staff will notify the company that its ordinary shares will be subject to delisting. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week.
